Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540)
- PMID: 9171870
- DOI: 10.1021/jm960726z
Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540)
Abstract
The synthetic pentasaccharide (1) corresponding to the heparin sequence which binds to, and activates, antithrombin III (AT III) is a potent antithrombotic compound in several animal models of venous thrombosis. We describe here the preparation and the pharmacological properties of 34, an analogue of oligosaccharide 1 with the latter's N-sulfates being replaced by sulfate esters and hydroxyl groups being methylated. These structural modifications allow a simpler and more efficient synthesis of such anionic oligosaccharides. Affinity for human AT III, anti-factor Xa activity, ability to inhibit thrombin generation, antithrombotic activity in a rat model of venous thrombosis, and elimination half-life in the rat have been determined for 1 and 34. Surprisingly, introduction of O-sulfates in place of N-sulfates, and methylation of hydroxyl groups, contributes to reinforce the binding to AT III, resulting in an improved pharmacological profile.
Similar articles
-
Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide.Semin Thromb Hemost. 1991;17 Suppl 1:112-7. Semin Thromb Hemost. 1991. PMID: 2068564
-
Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.Thromb Haemost. 2002 Feb;87(2):238-44. Thromb Haemost. 2002. PMID: 11858483
-
[From heparin to synthetic antithrombotic oligosaccharides].Bull Acad Natl Med. 2003;187(1):47-56; discussion 56-7. Bull Acad Natl Med. 2003. PMID: 14556453 French.
-
From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.Thromb Haemost. 2009 Nov;102(5):804-10. doi: 10.1160/TH09-01-0063. Thromb Haemost. 2009. PMID: 19888512 Review.
-
[New antithrombotic oligosaccharides].Ann Pharm Fr. 1999 May;57(3):232-9. Ann Pharm Fr. 1999. PMID: 10427858 Review. French.
Cited by
-
Carbohydrate-based drugs launched during 2000-2021.Acta Pharm Sin B. 2022 Oct;12(10):3783-3821. doi: 10.1016/j.apsb.2022.05.020. Epub 2022 May 23. Acta Pharm Sin B. 2022. PMID: 36213536 Free PMC article. Review.
-
Fondaparinux sodium.Drugs. 2002;62(11):1673-85; discussion 1686-7. doi: 10.2165/00003495-200262110-00007. Drugs. 2002. PMID: 12109927 Review.
-
Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery.Drugs. 2004;64(14):1575-96. doi: 10.2165/00003495-200464140-00005. Drugs. 2004. PMID: 15233593 Review.
-
Glomerular endothelial glycocalyx-derived heparan sulfate inhibits glomerular leukocyte influx and attenuates experimental glomerulonephritis.Front Mol Biosci. 2023 Jun 1;10:1177560. doi: 10.3389/fmolb.2023.1177560. eCollection 2023. Front Mol Biosci. 2023. PMID: 37325479 Free PMC article.
-
Fondaparinux: use in thromboprophylaxis of acute medical patients.Drugs Aging. 2008;25(1):81-8. doi: 10.2165/00002512-200825010-00009. Drugs Aging. 2008. PMID: 18184032 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Research Materials